Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Smith & Nephew plc (SNN) vs Uranium Energy Corp (UEC) Price & Performance

Smith & Nephew plcTrade
Uranium Energy CorpTrade

Price performance (Past 24H)

Key statistics

Smith & Nephew plc vs Uranium Energy Corp — how do they compare? Smith & Nephew plc trades at $29.77 (market cap $12.54B), while Uranium Energy Corp trades at $11.44 (market cap $5.67B). The key difference: Smith & Nephew plc is far larger — about 2.2× Uranium Energy Corp's market cap, and Smith & Nephew plc pays a 2.65% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.

SNNUEC
Market Cap
$12.54B$5.67B
Sector
HealthEnergy
52-Week High
$38.70$20.14
52-Week Low
$28.73$9.04
Enterprise Value
$15.57B$5.18B
Dividend Yield
2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Smith & Nephew plc

Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.

While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.

Uranium Energy Corp

UEC trades at $11.64, up 2.28% today, with a bullish technical signal from moving averages. The company reported a net loss of $87.66 million in 2025 despite $66.84 million revenue, with negative profit margins and cash flow challenges. Recent news highlights insider selling and ongoing uranium market optimism. Analyst consensus is strongly bullish with 87.5% buy ratings, though fundamentals show significant financial strain.

UEC presents high-risk exposure to uranium market growth with substantial operational losses and negative cash flow from operations. The stock's premium valuation (P/S 267.84) relies heavily on future nuclear energy adoption, while current financials indicate dependency on financing activities. Near-term catalysts include production ramp-up and licensing approvals, but execution risks and cost pressures remain elevated.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN

About Uranium Energy Corp

Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.

Read more on UEC